NCT02678117

Brief Summary

This study evaluates the effect of giving preoperative adjuvant drug as pregabalin or magnesium sulphate or a combination of both drugs to decrease postoperative morphine consumption and pain intensity in the first 24 hours in postoperative period . quarter of patients receive single dose oral pregabalin 300mg 1 hour preoperatively ,other quarter receive single intravenous Magnesium sulphate 50mg per Kg over 200ml saline over 20 minutes preoperatively , other quarter receive combination of both drugs , the last quarter receive placebo drugs . All patients receive 0.1mg per Kg intravenous morphine sulphate intraoperatively

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P25-P50 for phase_3 postoperative-pain

Timeline
Completed

Started Jul 2015

Longer than P75 for phase_3 postoperative-pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2015

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

February 5, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 9, 2016

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

September 22, 2021

Status Verified

September 1, 2021

Enrollment Period

4.4 years

First QC Date

February 5, 2016

Last Update Submit

September 21, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Total morphine consumption

    patients are given regular intravenous morphine through patient controlled analgesia (PCA) and morphine consumption calculated from the PCA device

    First 24 hours in postoperative period

Secondary Outcomes (9)

  • Pain intensity using Visual Analogue Scale

    First 24 hours in postoperative period

  • Recovery Time

    Immediately after ending the surgery

  • Heart Rate

    First 24 hours in postoperative period

  • Blood Pressure

    First 24 hours in postoperative period

  • Oxygen saturation

    First 24 hours in postoperative period

  • +4 more secondary outcomes

Study Arms (4)

Pregabalin & placebo

ACTIVE COMPARATOR

: will receive single dose oral Pregabalin 300 mg one hour preoperative and 200 ml of normal saline over 20 min.

Drug: Pregabalin & Placebo

Magnesium sulphate & Placebo

ACTIVE COMPARATOR

will receive preoperative single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline and a placebo capsule similar to pregabalin 300 mg.

Drug: Magnesium sulphate & Placebo

Pregabalin & Magnesium sulphate

ACTIVE COMPARATOR

: will receive single dose oral pregabalin 300mg one hour preoperative and single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline.

Drug: Pregabalin & Magnesium sulphate

Placebo

PLACEBO COMPARATOR

will receive placebo medications at the same time and route of administration of other groups.

Drug: Placebo

Interventions

Pregabalin & placebo
Magnesium sulphate & Placebo
Pregabalin & Magnesium sulphate
Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA status of1 or 2
  • Patients undergoing thoracotomy
  • Body mass index (BMI): Less than forty and more than twenty.

You may not qualify if:

  • \- 1. Known sensitivity or contraindication to drugs used in the study. 2. History of psychological disorders and/or chronic pain. 3. Patients receiving medical therapies that are considered to result in tolerance to opioids.
  • \. Significant liver or kidney diseases that will affects the pharmacokinetics of study drugs.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Cancer Institute

Cairo, 11796, Egypt

Location

Related Publications (3)

  • Sagit M, Yalcin S, Polat H, Korkmaz F, Cetinkaya S, Somdas MA. Efficacy of a single preoperative dose of pregabalin for postoperative pain after septoplasty. J Craniofac Surg. 2013 Mar;24(2):373-5. doi: 10.1097/SCS.0b013e31827fece5.

    PMID: 23524696BACKGROUND
  • Kiran S, Gupta R, Verma D. Evaluation of a single-dose of intravenous magnesium sulphate for prevention of postoperative pain after inguinal surgery. Indian J Anaesth. 2011 Jan;55(1):31-5. doi: 10.4103/0019-5049.76605.

    PMID: 21431050BACKGROUND
  • Salah Abdelgalil A, Shoukry AA, Kamel MA, Heikal AMY, Ahmed NA. Analgesic Potentials of Preoperative Oral Pregabalin, Intravenous Magnesium Sulfate, and their Combination in Acute Postthoracotomy Pain. Clin J Pain. 2019 Mar;35(3):247-251. doi: 10.1097/AJP.0000000000000673.

MeSH Terms

Conditions

Pain, Postoperative

Interventions

PregabalinMagnesium Sulfate

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

gamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and ProteinsMagnesium CompoundsInorganic ChemicalsSulfatesSulfuric AcidsSulfur AcidsSulfur Compounds

Study Officials

  • Naglaa A Ahmed, MD

    National Cancer Institute (NCI)

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Demonstrator in anaesthesia department, National Cancer Institute, Egypt

Study Record Dates

First Submitted

February 5, 2016

First Posted

February 9, 2016

Study Start

July 1, 2015

Primary Completion

December 1, 2019

Study Completion

December 1, 2019

Last Updated

September 22, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will share

De-identified individual participant data for all primary and secondary outcome measures will be available within 6 months of study completion

Locations